PMX464, a thiol-reactive quinol and putative thioredoxin inhibitor, inhibits NF-κB-dependent proinflammatory activation of alveolar epithelial cells by Callister, M E et al.
RESEARCH PAPER
PMX464, a thiol-reactive quinol and putative
thioredoxin inhibitor, inhibits NF-jB-dependent
proinflammatory activation of alveolar epithelial
cells
ME Callister
1, L Pinhu
1, MC Catley
2, AD Westwell
3, R Newton
4, SK Leaver
1, GJ Quinlan
1,
TW Evans
1, MJ Griffiths
1 and A Burke-Gaffney
1
1Critical Care, Critical Care, Pulmonary Vascular and Sleep Science, Respiratory Science, National Heart and Lung Institute, Faculty
of Medicine, Imperial College London, London, UK;
2Respiratory Pharmacology, Airways Disease, Respiratory Science, National Heart
and Lung Institute, Faculty of Medicine, Imperial College London, London, UK;
3Welsh School of Pharmacy, Cardiff University,
Cardiff, UK and
4Department of Cell Biology and Anatomy, University of Calgary, Alberta, Canada
Background and purpose: Subtle changes in the intracellular reduction–oxidation (redox) state can modulate nuclear factor-
kB (NF-kB) activity. Thioredoxin-1 (Trx) is a small, ubiquitous, redox-active thiol (-SH) protein that, with thioredoxin reductase-
1 (TrxR), modifies the redox status of NF-kB pathway components. PMX464 is a novel thiol-reactive quinol thought to inhibit
the Trx/TrxR system. The aim of this work was to investigate whether PMX464 inhibited NF-kB-mediated proinflammatory
activation of human type II alveolar epithelial cells (A549).
Experimental approach: Intercellular adhesion molecule-1 (ICAM-1), granulocyte-macrophage colony-stimulating factor
(GM-CSF) and CXCL8, NF-kB DNA binding, nuclear translocation of NF-kB p65 subunit, IkBa degradation, IkB
phosphorylation and IkB kinase (IKK) activity were assessed in A549 cells stimulated with IL-1b with or without PMX464
pretreatment. Effects of PMX464 on ICAM-1 expression in human lung microvascular endothelial cells (HLMVEC) were also
investigated. For comparison, selected measurements (ICAM-1 and IkB-a phospho-IkB-a) were made on A549 cells after RNA
interference-mediated silencing (siRNA) of Trx.
Key results: PMX464 reduced ICAM-1, GM-CSF and CXCL8 expression in IL-1b-stimulated A549 cells and ICAM-1 in HLMVEC.
PMX464 inhibited IL-1b-induced NF-kB DNA binding, nuclear translocation of NF-kB p65 subunit and factors involved in
NF-kB activation; specifically, IkBa degradation, IkB phosphorylation and IkB kinase (IKK) activity in A549. By contrast, Trx
siRNA did not alter ICAM-1 expression or IkBa degradation/phosphorylation in IL-1b-stimulated A549 cells.
Conclusion and implications: PMX464 inhibits a proinflammatory response in A549 cells targeting the NFkB pathway above
IKK. The lack of effect with Trx siRNA suggests that PMX464 acts on thiol proteins, in addition to Trx, to elicit anti-inflammatory
responses in lung epithelial cells.
British Journal of Pharmacology (2008) 155, 661–672; doi:10.1038/bjp.2008.258; published online 30 June 2008
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Abbreviations: GM-CSF, granulocyte macrophage-colony stimulating factor; HLMVEC, human lung microvascular endothelial
cells; ICAM-1, intercellular adhesion molecule-1; IFN, interferon; IKK, IkB kinase ; IL-1b, interleukin-1b;
IkB, inhibitor of NF-kB; NF-kB, nuclear factor kB; siRNA, short interference RNA; TNF, tumour necrosis factor;
Trx, thioredoxin, ; TrxR, thioredoxin reductase
Introduction
The transcription factor NF-kB plays a pivotal role in the
expression of a wide range of genes involved in lung
inflammation, including the chemokine CXCL8 (inter-
leukin-8; IL-8), granulocyte macrophage-colony stimulating
factor (GM-CSF) and intercellular adhesion molecule-1
(ICAM-1) (Lentsch and Ward, 2000). In unstimulated cells,
NF-kB proteins are sequestered in the cytosol through
interactions with inhibitory proteins (IkBa, b and e). Tumour
necrosis factor-a (TNF-a), interleukin-1 (IL-1b), bacterial
products and oxidants cause phosphorylation and degrada-
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pathway. Free NF-kB enters the nucleus and induces gene
expression. Phosphorylation of IkBb yI kB kinase (IKK)
complex is a point at which diverse signals converge to
activate NF-kB. Key components of the IKK complex are
IKK-a and IKK-b, also termed IKK-1 and -2 (Ghosh and
Karin, 2002). Of the drug development strategies currently
being pursued for inhibition of the NF-kB pathway, targeting
IKK-b activity shows considerable potential as an anti-
inflammatory therapeutic strategy (Birrell et al., 2005; Catley
et al., 2005).
Subtle changes in intracellular reduction–oxidation
(redox) state also modulate NF-kB activity and thus impact
on the pulmonary inflammatory response (Rahman et al.,
2006). Expression of thioredoxin (Trx), a small, ubiquitous
thiol [sulphydryl (-SH)] protein involved in intracellular
redox control, is raised during conditions associated with
lung inflammation (Koura et al., 2000; Tiitto et al., 2003;
Callister et al., 2006) and Trx is also known to regulate
components of the NF-kB pathway (Lillig and Holmgrem,
2007). The key to Trx redox activity lies in the two cysteine
residues (Cys32 and Cys35) separated by two amino acids
(Gly-Pro) in the active site. These cysteines exist as a dithiol
(-[SH]2) in the reduced form and a disulphide (-S2) in the
oxidized form. Trx is oxidized when it transfers ‘reducing
equivalents’ to disulphide groups in target proteins and is
reduced back to the dithiol form by an nicotinamide
adenine dinucleotide phosphate (reduced form); (NADPH)-
dependent flavoprotein, thioredoxin reductase. Altogether,
these enzymes and cofactors form the ‘Trx system’
(Burke-Gaffney et al., 2005).
In the past decade, biological screening has identified
several small organic compounds that inhibit the Trx system.
PMX464 (previously AW464) is one of a group of (hetero)
aromatic 4-hydroxycyclohexa-2,5-dienones (‘quinols’),
which inhibit Trx redox cycling by forming an irreversible
complex with the active-site thiol groups in the reduced
form of Trx (Wells et al., 2003). Previous studies with
PMX464 have shown antiproliferative effects on tumour cell
lines and endothelial cells, in part, through the effects on
hypoxia inducible factor-1a transcription factor and vascular
endothelial growth factor release (Mukherjee et al., 2005,
2007). In addition to studies with pharmacological inhibi-
tors, recent advances in post-transcriptional gene silencing
using short interference RNAs (siRNAs), have provided
another approach to downregulating expression of intracel-
lular proteins and thus for evaluating the role of the Trx/TrxR
system in cellular processes (Gorreta et al., 2005; Ravi et al.,
2005; Freeman and Neuzil, 2006; Trigona et al., 2006).
The aim of the current study was to investigate the effect
of PMX464 on the expression and function of markers of
inflammation in the human alveolar epithelial cell line,
A549. PMX464 reduced function and/ or expression of
ICAM-1, CXCL8 and granulocyte-macrophage colony-stimu-
lating factor (GM-CSF) and also activation of the NF-kB
pathway subsequent to the inhibition of IKK activity.
Likewise, PMX464 reduced ICAM-1 expression/function in
normal human lung microvascular endothelial cells
(HLMVEC). However, as Trx siRNA did not inhibit ICAM-1
expression or IkB-a degradation/phosphorylation in IL-1b-
stimulated A549 cells, these results suggest that PMX464 has
anti-inflammatory effects in lung epithelial cells that could
be, at least in part, independent of direct effects on Trx.
Materials and methods
Cells
Human type II alveolar cell lines (A549, ECACC 86012804,
European Collection of Cell Cultures, Porton Down, Salis-
bury, Wiltshire, UK) were maintained as described previously
(Burke-Gaffney and Hellewell, 1996). 6kB cells, A549 cells
harbouring the 6kB.tk luciferase reporter, were prepared as
described previously (Bergmann et al., 1998). HLMVEC were
purchased from Cambrex (Wokingham, UK) and were
maintained as previously described (Blease et al., 1999).
Cell viability
Viability was assessed using a method based on the mito-
chondrial reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide to formazan as described
previously (Burke-Gaffney and Hellewell, 1996). Preliminary
screening experiments were carried out to select effective
inhibitor concentrations and conditions that were not toxic
to cells. Thus, for A549, cells were treated with PMX464
(10 and 30mM) for 30min and then the inhibitor was removed
before cytokine treatment for 24h. By contrast, HLMVEC
were preincubated with PMX464 (0.6, 1mM) for 30min
followed by the addition of cytokines to the PMX464 for
24h. The difference in protocols could reflect a previously
published observation that A549 cells are more resistant than
endothelial cells to intracellular redox disturbance (Dandreaa
et al., 2002) and are therefore likely to require higher con-
centrations of PMX464 to disrupt inflammatory signalling.
ELISA measurement
A549 were seeded at 10
4 cells cm
 2 into 96-well plates and
after 2 days confluent monolayers were treated for 30min
with PMX464, which was then removed and IL-1b, TNF-a
and interferon-g (IFN-g) added for 24h. HLMVEC were
seeded at 4.7 10
4 cells cm
 2 and were confluent 4–5 days
later. Supernatants were collected and assayed by ELISA for
secretion of CXCL8 or granulocyte-macrophage colony-
stimulating factor (GM-CSF) (R & D Systems, Abingdon,
Oxford, UK). After removal of supernatants, ICAM-1 was
detected by ELISA on the cell surface as described previously
(Blease et al., 1999). A549 cells were also plated at
3.1 10
4cellscm
 2 in 6-well plates and at confluence were
treated with PMX464 or AS602868 for 30min and then IL-1b
for 1h. Whole cell extracts were prepared and ELISA based
Trans-AM kits (Active Motif, Rixensart, Belgium) used to
assess NF-kB p50 and p65 binding activity according to the
manufacturer’s protocol (Gupta et al., 2002). Results are
expressed as optical density (OD)405 per milligram protein.
RNA isolation and reverse transcriptase-PCR
Total cellular mRNA was isolated from unstimulated, IL-1b,
PMX464 and IL-1b plus PMX464 treated cells using
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converted into cDNA and regions of interest amplified using
PCR as described previously (Blease et al., 1999). PCR
fragments were resolved using agarose gel (1%) electro-
phoresis. Values for ICAM-1 expression were determined by
densitometry and normalized to b-actin mRNA levels for
each experimental condition.
Adhesion and migration assays
Neutrophils isolated from human peripheral blood by
discontinuous plasma/percoll density gradient centrifuga-
tion were labelled with a florescent dye, Calcein-AM, as
described previously (Blease et al., 1999). For adhesion
assays, labelled neutrophils were resuspended at
1.25 10
6cellsmL
 1 and 100mL added to A549 monolayers
that had been pretreated (and stimuli removed) with IL-1b
plus or minus PMX464. Adhesion was measured and
expressed as percent adherent neutrophils, as described
previously (Blease et al., 1999). For migration assays, super-
natants from A549 monolayers treated for adhesion experi-
ments were diluted 1:10 and placed in wells of ChemoTx
chemotaxis plates (Neutroprobe, Receptor Technologies,
Gaithersburg, MD). Labelled neutrophils (25mLo f
3 10
6cellsmL
 1) were placed on porous membranes
(0.8mm pores) positioned above wells containing stimuli or
conditioned medium. Total fluorescence of 25mL of labelled
neutrophils and also fluorescence in wells after 60min of
migration was measured using a Biolite F1 plate reader
(Labtech International, Ringmer, East Sussex, UK). Migration
was expressed as percentage of neutrophils migrating to the
lower chamber.
Luciferase assay
6kB cells were plated at 5 10
4 cells cm
 2 in 24-well plates
and treated with IL-1b or TNF-a (8h) plus or minus PMX464
or the IKK-2 inhibitor, AS602868. Luciferase activity was
measured in cell lysates using luciferase substrate (Promega,
Southampton, UK) according to the manufacturer’s protocol.
Luciferase activity was measured using an automated
luminometer (Fluostar Optima Microplate reader, BMG,
Offenburg, Germany) and normalized to the total protein
concentration for each well. Results were expressed as
luciferase activity units (mgprotein)
 1.
Immunofluorescence staining and confocal microscopy
Cells were plated onto sterilized glass cover slips in 24-well
plates (4 10cellscm
 2), left overnight and then treated
with medium or PMX464 for 30min followed by medium or
IL-1b for 1h. Cells were fixed, permeabilized and incubated,
first, with rabbit antihuman p65 antibody and, secondly,
with donkey antirabbit IgG antibody conjugated to Alexa
488 (stains p65 green). Cells were counterstained with 1%
Evans blue solution (stains cytoplasm red) and images
acquired using a Leica TCS 4D microscope at 488nm for
p65 and 568nm for cytoplasmic counterstaining.
Immunoblotting
Cells were plated at 3.1 10
4 cellscm
 2 into 6-well plates,
treated with medium or PMX464 for 30min followed by
medium or IL-1b for times between 5min and 3h. Cell lysate
was separated on (4–12%) SDS-polyacrylamide gel electro-
phoresis and probed with mouse polyclonal antihuman
IkB-a (1:1000 dilution), mouse polyclonal antihuman phos-
phorylated IkB-a (1:2000 dilution) and mouse polyclonal
antihuman b-actin (1:4000 dilution). The intensity of signal
was quantified using densitometry and the values expressed
as a ratio of b-actin band density.
Kinase assay
The in vitro kinase assay was performed as described
previously (Catley et al., 2004). A549 cells in 6-well plates
were incubated for 30min with medium, PMX464 or
PS-1145 (a specific and reversible IKK-2 inhibitor) followed
by IL-1b for 3min. Cells were then washed and cytoplasmic
extracts prepared and precleared for 1h using normal goat
IgG agarose conjugated antibody. IKK-g was precipitated
from 200mg of total protein using an agarose conjugated
goat antihuman IKK-g antibody for 2h at 41C. The
immunoprecipitate was incubated at 371C for 1h in kinase
reaction buffer containing [g-
32P] ATP (80mCimL
 1;
Amersham Bioscience, Little Chalfont, Buckinghamshire,
UK) and a recombinant IKK substrate peptide (Upstate
Biotechonology, Charlottesville, VA, USA). In selected
experiments, PMX464 and PS-1145 were added directly to
the kinase assay. Reactions were stopped and samples run on
12% NUPAGE SDS-PAGE gels (Invitrogen, Carlsbad, CA,
USA). The gels were then cut at the 28KDa marker and the
upper portion analysed by Western blotting to determine
equal loading of IKK-2, whereas the lower portion of the gel
containing the substrate peptide was analysed by autoradio-
graphy.
Thioredoxin activity assay
The redox activity of pure Trx or that in lysates of A549 cells
was assessed using a modification of the insulin reduction
assay described by Holmgren and Bjornstedt (1995). Briefly,
Trx or cell lysate together with PMX464 were added to a
reaction mixture containing 6.4mgmL
 1 insulin and in-
cubated at 371C for 20min. The reaction was stopped and
OD412 and corrected for protein content of cell lysate
samples.
Transfection with siRNA
Two target-specific siRNAs against Trx were designed and
synthesized by Dharmacon (Lafayette, CO, USA, sense,
GUGAUAAACUUGUAGUAGUUU); and Santa Cruz Biotech-
nology (a pool of three strands against Trx mRNA; sense,
CAUCCCUGGUGACAAAGAATT, GAAGGGAUGCAUCCAU
GAATT, and GCGAUCAACUCUAGCCAAATT). As a control,
two non-targeting ‘scrambled’ siRNA were used (Dharmacon
and Santa Cruz). Cells were seeded at 2 10
4cells per well
onto 24-well plates and were transfected at 30–40% con-
fluence approximately 16–24h later, using a mixture of
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Genesilencer siRNA transfection reagent (Genlantis, San
Diego, CA, USA), according to the manufacturer’s instruc-
tions. Cells were either harvested 72h after transfection and
20mg of protein analysed by western blotting to confirm
knockdown or stimulated for 5min or 24h with IL-1b
(0.3ngmL
 1) before measuring IkB-a degradation and
phospho-IkB-a (5min) or ICAM-1 (24h).
Statistics
Results are expressed as mean±s.e.m. of n experiments.
Statistical analysis was carried out using a one-way ANOVA
followed by the Bonferroni post-test. Data were log trans-
formed before analysis, if variances were significantly
different by Bartlett’s test. Graphpad Prism version 3.03
(GraphPad, San Diego, CA, USA) was used to perform
statistical analysis; results were deemed significant if
Po0.05.
Recombinant proteins and reagents
Human IL-1b, TNF-a and IFN-g were purchased from Roche,
(Lewes, East Sussex, UK). PMX464 (4-(benzothiazol-2-yl)-4-
hydroxycyclohexa-2,5-dien-1-one hydrate) was synthesized
according to a previously described method (Wells et al.,
2003). 3-(4, 5-dimethyl-2-thiazolyl)-2,5- diphenyl tetrazo-
lium bromide was from Sigma Aldrich (Poole, Dorset, UK).
Rabbit polyclonal antihuman IkBa (sc-371), rabbit polyclo-
nal antihuman p65 antibody (sc109) and agarose conjugated
goat antihuman IKK-g antibody were from Autogen Bioclear
(Calne, Wiltshire, UK); mouse polyclonal antihuman phos-
phorylated (Ser 32 and 36) IkB-a (New England Biolabs,
Hitchin, Hertfordshire, UK); and mouse polyclonal antihu-
man b-actin (AC-15, Sigma Aldrich); anti-Trx antibody
(Santa Cruz Biotechnology, Santa Cruz, CA, USA); donkey
polyclonal antirabbit IgG antibody conjugated to Alexa 488
and Calcein-AM (Cambridge Bioscience, Cambridge, UK);
PS-1145 (N-(6-chloro-9H-b-carbolin-8-ly) nicotinamide) was
a gift from Millennium Pharmaceuticals (Cambridge, MA,
USA) and AS602868 from Serono (Geneva, Switzerland).
AS602868 is an anilinopyrimidine derivative and ATP
competitor, which inhibits IKK-2 (patent application
PCTWO 02/46171). Human Trx was from IMCO (Stockholm,
Sweden).
All drug and molecular target nomenclature conforms to
the British Journal of Pharmacology’s Guide to Receptors and
Channels (Alexander et al., 2008).
Results
PMX464 inhibits proinflammatory gene expression and function
in A549 alveolar epithelial cells
Constitutive ICAM-1 was detected on non-stimulated A549
cells. Submaximal concentrations of cytokines were chosen
to activate A549 cells, based on preliminary experiments
(data not shown) and our previously published study (Burke-
Gaffney and Hellewell, 1996), to facilitate the detection of
inhibitory effects with PMX464. Incubation with TNF-a
2ngmL
 1), IL-1b (0.3ngmL
 1) and IFN-g (5ngmL
 1) sig-
nificantly (Po0.001) increased ICAM-1 expression
(Figure 1a). Pretreatment with 10 and 30mM PMX464
reduced IL-1b- and TNF-a-, but not IFN-g -induced, ICAM-1
expression (Figure 1a). PMX464 abolished IL-1b-induced
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Figure 1 PMX464 reduces expression of ICAM-1 protein and
mRNA in A549 cells. A549 monolayers were preincubated with
medium or PMX464 (10, 30mM) for 30min, then exposed to TNF-a
(2ngmL
 1), IL-1b (0.3ngmL
 1), IFN-g (5ngmL
 1) or medium for
24h. ICAM-1 expression was determined by ELISA and data are
shown as mean±s.e.m. (n¼5; a). A549 monolayers were also
preincubated with medium or PMX464 (30mM) for 30min, then
exposed to IL-1b (0.3ngmL
 1) or medium for 4h. ICAM-1 mRNA
levels were quantified by RT-PCR and compared to levels of b-actin
mRNA and data shown as a representative blot for ICAM-1 and
b-actin mRNA (b) and the ICAM-1/bactin ratio (normalized to the
ratio for medium alone, n¼5, (c)). *Po0.05, **Po0.01,
***Po0.001, asterisks above the bars indicate comparison with
basal expression and those on connecting lines indicate comparison
between these conditions. ICAM-1, intercellular adhesion molecule-
1; IFN, interferon; IL, interleukin, RT-PCR, reverse transcriptase-PCR.
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control b-actin were not altered (Figures 1b and c). PMX464
also reduced IL-1b- and TNF-a-induced expression of CXCL8
and GM-CSF in A549 (Figures 2a and b).
A functional consequence of ICAM-1 expression is neu-
trophil adhesion. The percentage of neutrophils adherent to
A549 cells pretreated with PMX464 and IL-1b (0.3ngmL
 1)
was significantly less than that to A549 cells exposed only to
IL-1b (Figure 3a). A functional consequence of CXCL8 release
is neutrophil migration. Supernatants collected from
PMX464/IL-1-b-treated A549 cells caused significantly less
neutrophil migration than the supernatants from A549 cells
treated only with IL-1b (0.3ngmL
 1; Figure 3b). Neither
IL-1b nor PMX464 had any direct effect on neutrophil
migration (data not shown).
Inhibitory effects with PMX464 were not limited to A549
alveolar epithelial cells as treatment of HLMVEC with
PMX464 also reduced cytokine-induced ICAM-1 expression
(Table 1). As seen with A549 cells, PMX464 (1mM) also
significantly (Po0.05) reduced IL-1b-( 1 n g m L
 1) induced
ICAM-1 mRNA in HLMVEC from an ICAM-1/b-actin ratio of
Figure 2 PMX464 reduces CXCL8 (IL-8) and GM-CSF release from
A549 cells. A549 monolayers were preincubated with medium or
PMX464 (10, 30mM) for 30min, then exposed to TNF-a (2ngmL
 1)
or IL-1b (0.3ngmL
 1) for 24h. CXCL8 (a) and GM-CSF (b)
expression were determined by ELISA and data are shown as
mean±s.e.m. (n¼8 for CXCL8; n¼5 for GM-CSF). *Po0.01,
**Po0.001, asterisks above the bars indicate comparison with basal
expression and those on connecting lines indicate comparison
between these conditions. GM-CSF, granulocyte-macrophage
colony-stimulating factor; ICAM-1, intercellular adhesion molecule-1;
TNF, tumour necrosis factor; IL, interleukin.
Figure 3 PMX464 inhibits neutrophil adhesion and migration, in
vitro. Fluorescently-labelled neutrophils were placed onto A549
monolayers that had been preincubated with PMX464 (30mM) for
30min, exposed to IL-1b (0.3ngmL
 1) for 24h and stimuli removed
before adding neutrophils. After 30min, non-adherent cells were
removed by washing, fluorescence measured and the number of
neutrophils adhering expressed as a percentage±s.e.m. of total
neutrophils added (n¼6, a). For migration assays, A549 monolayers
were treated as above with PMX464 and IL-1b then the supernatants
were collected and diluted 1:10, put into the lower chambers of the
chemotaxis plate and then fluorescently-labelled neutrophils were
placed on the porous membranes above. After 60min, fluorescence
in the lower chamber was measured and the number of migrating
neutrophils expressed as a percentage±s.e.m. of total neutrophils
placed on the top chamber (n¼6, b). *Po0.05, ***Po0.001,
asterisks above the bars refer to comparison with basal adhesion or
migration and those above lines refer to comparison between
indicated conditions. IL, interleukin.
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sion to IL-1b/PMX464-treated HLMVEC monolayers was also
significantly (Po0.01) reduced (8.3±0.3% adhesion, n¼4)
compared with adhesion to HLMVEC treated with IL-1b
alone (19.4±2.9% adhesion, n¼4). PMX464 also inhibited
CXCL8 release from HLMVEC (data not shown).
PMX464 inhibits NF-kB activation in A549 cells
We have reported previously using a variety of techniques,
including small molecule inhibitors of IKK, that IL-1b-
induced ICAM-1 and CXCL8 expression in A549 cells is
NF-kB dependent (Catley et al., 2005; Newton et al., 2007). In
this study we investigated the effect of PMX464 on NF-kB
activation in A549 cells. First, we looked at the effect of
PMX464 on NF-kB-dependent transcription in A549 cells
containing an NF-kB-dependent reporter gene (6kB cells).
PMX464 and for comparison AS602868, an IKK-2 inhibitor,
reduced IL-1b- (0.3ngmL
 1), and TNF-a-induced luciferase
reporter activity back to basal levels (Figure 4). Next, we
assessed the inhibitory effect of PMX464 on the DNA
binding activity of NF-kB p65 and p50 subunits present in
A549 cell lysates using Trans-AM transcription factor assays.
Binding of both p65 and p50 increased in cells treated for 1h
with IL-1b (0.3ngmL
 1), compared to control cells, and
preincubation with PMX464 abolished p65 and p50 binding
activity (Figure 5a). Basal binding activity was also reduced
with PMX464 alone. Similar effects were seen with AS602868
(Figure 5b).
Immunostaining and confocal microscopy were used to
determine the subcellular distribution of p65 in A549 cells
and the effect of PMX464 on its distribution. In resting and
PMX464-treated cells, the p65 subunit was located in the
cytoplasm, whereas in IL-1b-(0.3ngmL
 1) treated cells, p65
was detected in the nucleus. When cells were pretreated with
PMX464 followed by IL-1b, p65 remained in the cytoplasm
(Figure 6). Similarly, cells pretreated with AS602868 before
IL-1b also showed that p65 remained, predominantly, in the
cytoplasm (Figure 6). The reason for the brighter red staining
of the cytoplasm in cells treated with AS602868 is not clear.
However, in this and two further experiments, AS602868 and
PMX464 clearly prevented translocation of p65 into the
nucleus of A549 cells.
PMX464 inhibits rapid degradation and phosphorylation of IkB-a
in IL-1b-treated A549 cells
NF-kB activity is controlled by the steady state level of IkB.
Thus, we analysed the effect of PMX464 on IL-1b-induced
IkBa degradation by western blotting. IL-1b (0.3ngmL
 1)
induced a rapid loss of IkBa with reexpression after 60min
(Figure 7). PMX464 prevented the rapid, initial loss of IkBa in
IL-1b-treated cells and, instead induced a more gradual
decline in protein levels over a 6h period.
A key step required before degradation of IkB-a is IKK-2-
dependent phosphorylation of the N-terminal residues Ser32
and Ser36. Using a specific IkB-a phosphoserine antibody, we
showed that phosphorylated IkBa was detected in IL-1b
(0.3ngmL
 1) treated cells at 5 or 15min and also at 2h
(Figure 8). PMX464 prevented IL-1b-induced phosphoryla-
tion of IkB-a at all times between 5min and 3h (Figure 8).
PMX464 inhibits activation of processes upstream of the IKK
complex in IL-1b-treated A549 cells
A decrease in IL-1b-induced IkBa phosphorylation with
PMX464 suggests a possible effect on IKK complex activa-
tion. To investigate this, the IKK complex was immunopre-
cipitated from A549 cells and ability of the complex to
phosphorylate a substrate peptide was assessed using kinase
assays. IL-1b- (0.3ngmL
 1) treated cells showed high levels
of IKK activity, whereas activity from cells pretreated with
Table 1 PMX464 inhibits ICAM-1 expression in HLMVEC
Medium (OD405)T N F - a (OD405) IL-1b (OD405)
Medium 0.16±0.02 0.98±0.05 0.86±0.05
PMX464 0.6mM 0.11±0.02 0.77±0.04** 0.69±0.03*
PMX464 1mM 0.12±0.02 0.62±0.04*** 0.57±0.03***
Abbreviations: HLMVEC, human lung microvascular endothelial cells; ICAM-1,
intercellular adhesion molecule-1; IL, interleukin; TNF, tumour necrosis
factor.HLMVEC, monolayers were preincubated with medium or PMX464
(0.6, 1mM) for 30min. TNF-a (0.3ngmL
 1), IL-1b (1ngmL
 1) or medium was
added to PMX464 for a further 24h. ICAM-1 expression was determined by
ELISA and data are shown as mean±s.e.m. (n¼5). *Po0.05, **Po0.01,
***Po0.001 when compared to ICAM-1 expression with cytokine but without
PMX 464.
Figure 4 PMX464 and AS602868 inhibit luciferase activity in A549
cells containing an NF-kB-dependent reporter gene (6kB cells). A549
cells stably transfected with the NF-kB reporter, 6NF-kB.tk luc (6kB),
were preincubated for 30min with PMX464 (30mM), AS602868
(10mM) or 0.01% DMSO vehicle (V) and then for 8h with TNF-a
(2ngmL
 1), IL-1b (0.3ngmL
 1) or medium. Luc activity for each
condition (corrected for protein) was expressed as a proportion of
baseline luc activity and data are expressed as mean±s.e.m. (n¼4).
*Po0.01, **Po0.001, asterisks above the bars refer to comparison
with basal activity and those above lines refer to comparison
between conditions. IL, interleukin; Luc, luciferase; NF-kB, nuclear
factor-kB; TNF, tumour necrosis factor.
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Experiments in which treatments are added onto cells rather
than directly onto the kinase assay are marked as OC in
Figure 9. Treatment of A549 cells with the specific IKK-2
inhibitor, PS-1145 (Hideshima et al., 2002; Castro et al.,
2003), did not inhibit IKK complex activity (Figure 9, OC),
because it is a reversible inhibitor that washes off the
complex during purification. These results suggest that
PMX464 works as either a non-reversible inhibitor of the
IKK complex or inhibits activation of IKK complex at an
upstream step.
To investigate this, the IKK complex was immunoprecipi-
tated from IL-1b- (0.3ngmL
 1) treated A549 cells and then
added onto kinases assays with or without PMX464 or PS-
1145. These treatments are indicated OA in Figure 9. Applied
in this manner, PS1145 but not PMX464 inhibited IKK
activity (Figure 9). This suggests that PMX464 does not
inhibit the IKK complex, directly, but most likely inhibits
IKK activity at some upstream step. Similar data were
obtained when TNF-a (2ngmL
 1) replaced IL-1b in these
experiments (data not shown). The upstream process
inhibited is thus likely to be common to the IL-1b and
TNF-a pathways.
PMX464 is unlikely to be a general suppressor of cell
signalling as phosphorylation of p38 and ERK in PMX464/IL-
1b-treated A549 was not decreased compared to treatment
with IL-1 (0.3ngmL
 1) alone (data not shown). Moreover,
PMX464 is not an indiscriminate thiol inhibitor, because it
fails to inhibit ficin a proteolytic enzyme, which contains an
essential thiol (unpublished data, personal communication
Dr T Bradshaw, University of Nottingham). In summary,
these data suggest that PMX464 inhibited IL-1b-induced
NF-kB activation by preventing processes leading to the
activation of the IKK complex.
Trx siRNAs did not inhibit IL-1b-induced CXCL8 release,
nor ICAM-1 expression or IKK activity in A549
One likely candidate for the upstream target of PMX464 is
Trx. As previously reported (Pallis et al., 2003), we confirmed
that the preincubation of Trx with PMX464 (30mM) inhibited
redox activity of Trx by 68% (n¼3). The IC50 for this reaction
was calculated to be 20mM. Moreover, we also showed that
when A549 cells were treated for 30min with PMX464
(30mM), the cell lysates showed significantly diminished
(26%, Po0.01) insulin reducing activity compared with the
activity in untreated A549 cells (n¼6). These results suggest
that PMX464 inhibits, at least in part, redox activity of the
Trx system in A549 cells.
By western blotting, we showed that a combination of two
different siRNA sequences that specifically target Trx lowered
Trx in A549 by 70% (Figures 10a and b). However, neither
intracellular levels of IkB-a or phosphorylated IkBa nor
expression of ICAM-1 changed in siRNA-treated cells despite
positive effects with PMX464 and AS602868 (Figures 10b and
Figure 5 PMX464 and AS602868 prevent DNA-binding activity of
p65 and p50 subunits of NF-kB in A549 cells. A549 monolayers were
preincubated for 30min with PMX464 (30mM; a), AS602868 (10mM;
b) or medium and then for 1h with IL-1b (0.3ngmL
 1) or medium.
DNA-binding activity of p65 and p50 in whole cell extracts were
measured using TransAM transcription factors assays and results
expressed as mean OD450 per milligram protein±s.e.m. (n¼5).
*Po0.01, **Po0.001, asterisks above the bars refer to comparison
with basal activity and those above lines refer to comparison between
conditions. IL, interleukin; NF-kB, nuclear factor-kB.
Figure 6 PMX464 and AS602868 alter cellular localization of p65
in A549 cells as assessed by confocal microscopy. Cells were
preincubated for 30min with PMX464 (30mM), AS602868 (10mM)
or medium and then for 1h with IL-1b (0.3ngmL
 1) or medium.
The p65 subunit of NF-kB was indirectly immunostained with
Alexa 488-labelled antibody (green) and Evans blue (red) was used
to counterstain cell cytoplasm. Images from an experiment
representative of three separate experiments are shown. NF-kB,
nuclear factor-kB.
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when Trx content was reduced with siRNA nor did a control,
scrambled siRNA, have any effect on Trx protein expression
(data not shown).
Discussion
Accumulation of neutrophils in the lung is a key event in the
onset and development of lung inflammation and injury.
Thus, blocking the processes contributing to neutrophil
accumulation, namely adhesion and migration, remains an
attractive target for anti-inflammatory therapies in lung
disorders. In this study, we showed that the novel quinol
compound and putative Trx inhibitor, PMX464, inhibited
IL-1b-induced ICAM-1 expression and, correspondingly,
reduced neutrophil adhesion to A549 epithelial cells.
PMX464 also abolished GM-CSF and reduced CXCL8 release
and the supernatants collected from IL-1b/PMX464-treated
cells had reduced chemotactic ability. PMX464 showed
similar inhibitory effects on ICAM-1 function and expression
in HLMVEC. This finding suggests that the inhibitory effect
of PMX464 on inflammatory markers is not limited to an
alveolar epithelial cell line and moreover, it suggests that
PMX464 could have therapeutic potential for the treatment
of lung inflammatory disorders targeting endothelial cells in
addition to epithelial cells. To our knowledge, this is the first
study to report anti-inflammatory properties of PMX464.
Our findings with the PMX464, showing the inhibition of
key processes involved in leukocyte recruitment, support
two previous studies that showed a reduction of neutrophil
and eosinophil accumulation in mouse models of intestinal
ischaemia-reperfusion injury (Souza et al., 2005) and asthma
(Henderson et al., 2002), respectively, with a structurally
unrelated Trx inhibitor, MOL294. We also have unpublished
data showing MOL294, like PMX464, reduced cytokine-
induced ICAM-1 expression in A549 cells. Prompted by a
further study showing that MOL294 inhibited NF-kB (Misra-
Press et al., 2002) and the large body of evidence linking
activation of the NF-kB pathway to lung inflammation,
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Figure 7 PMX464 delays IL-1b-induced degradation of IkB-a. A549
monolayers were preincubated for 30min with PMX464 (30mM)o r
medium and then for times up to 360min with IL-1b (0.3ngmL
 1).
Western blots were performed on cell lysates and membranes
probed for total IkB-a protein and b-actin as a loading control.
Representative blots are shown for cells stimulated with IL-1b alone
(a) and also cells preincubated with PMX464 and then exposed to
IL-1b (b). The mean ratio of IkB-a/b-actin±s.e.m. (arbitrary units) for
five separate experiments is also shown (c). *Po0.05, ***Po0.001
when conditions with and without PMX464 were compared using
repeated measures ANOVA with mixed model to confirm results. IL,
interleukin; NF-kB, nuclear factor-kB.
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Figure 8 PMX464 prevented IL-1b-induced phosphorylation of
IkB-a. A549 monolayers were incubated for 30min with PMX464 or
medium and then for times up to 360min with IL-1b (0.3ngmL
 1).
Western blots were performed on cell lysates and membranes
probed for phosphorylated IkB-a protein (Ser
32 and Ser
36) and
b-actin as a loading control. Representative blots are shown for cells
stimulated with IL-1b alone (a) and cells preincubated with PMX464
before IL-1b stimulation (b). The mean ratio for phospho-IkB-a/b-
actin±s.e.m. (arbitrary units) for five separate experiments is also
shown (c). *Po0.05, **Po0.01 when conditions with and without
PMX464 were compared using repeated measures ANOVA with
mixed model to confirm results. IL, interleukin.
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British Journal of Pharmacology (2008) 155 661–672we proposed to investigate whether PMX464 would also
inhibit the NF-kB pathway in A549 lung epithelial cells.
First, PMX464 was compared with AS602868, a known
NF-kB inhibitor. Both inhibitors prevented cytokine-induced
NF-kB controlled luciferase reporter activity suggesting that
PMX464 has NF-kB inhibitory activity. AS602868, but not
PMX464, reduced basal activity. AS602868 competes with
ATP for binding to IKK-2 (Frelin et al., 2003). PMX464 is
unlikely to compete with ATP and this probably accounts for
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Figure 9 PMX464 inhibits IL-1b-induced activity of IkB-kinase
complex immunoprecipitated from A549 cells. A549 monolayers
were incubated for 3min with either medium or IL-1b (0.3ngmL
 1).
IKK complex was immunoprecipitated from A549 cell lysates using
an anti-IKK-g antibody. Immunoprecipitates were divided in two and
one-half was subjected to IKK kinase assay using GST-IkB-a as a
substrate (upper panel) and the other half to western blot analysis for
IKK-b (lower panel). In some experiments, A549 cells were
preincubated for 30min with PMX464 (30mM) or PS-1145 (10mM)
then for 3min with IL-1b or medium. These experiments were
designated OC (on cells) meaning that the inhibitor is added onto
the cells and not directly onto the kinase assay. For other
experiments, IKK was immunoprecipitated from IL-1b-stimulated
cells and PMX464 (30mM) or PS-1145 (10mM) added directly to the
kinase assay. These experiments were designated OA (on assay),
meaning that the inhibitor is added to IKK complex and not
incubated with the cells. Control experiments were also performed
in which the anti-IKK-g antibody was omitted from the immuno-
precipitation protocol (PI) and also in which an equivalent
concentration of vehicle (DMSO) was used instead of inhibitor.
Results show a blot representative of three similar experiments. IKK,
IkB kinase; IL, interleukin.
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Figure 10 Knockdown of Trx with siRNA did not alter IL-1b-
induced levels of IkB-a or ICAM-1 expression. A549 monolayers were
incubated with Trx siRNA (200nM) and used in experiments 72h
later. Trx levels in A549 cells were determined by western blot on cell
lysates and results are shown as a representative blot (a) and as a
ratio to b-actin (n¼5, b). A549 monolayers were transfected with
Trx siRNA or preincubated for 30min with PMX464 (10mM)o r
AS602868 (10mM before exposure to IL-1b (0.3ngmL
 1, 30min).
Western blots were performed on cell lysates to measure phos-
phorylated Ser
32 and Ser
36 IkB-a, total IkB-a, and b-actin as a loading
control and a representative blot is shown (c). A549 cells were also
exposed to Trx siRNA or inhibitor then treated with IL-1b or medium
(24h) and ICAM-1 measured (d). Results show expression (OD405)
±s.e.m. (n¼5). ***Po0.001; asterisks above the bars refer to
comparison with basal expression and those above connecting lines
refer to comparison between conditions indicated. Trx, thioredoxin-
1; siRNA, short interference RNA; ICAM-1, intercellular adhesion
molecule-1; IL, interleukin.
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compounds. PMX464 inhibited IL-1b-induced NF-kB-con-
trolled reporter luciferase activity by 90%. A similar level of
inhibition was also seen with PMX464 on IL-1b-induced
DNA-binding activity of the p50 and p65 subunits of NF-kB.
Immunostaining of A549 cells, in conjunction with
confocal microscopy, showed that PMX464 prevents move-
ment of p65 from the cytoplasm to the nucleus in IL-1b
treated cells.
The nuclear localization domain of p65 binds to IkB. Most
pharmacological inhibitors that prevent NF-kB translocation
do so by preventing IkB degradation. Thus, it was reasonable
to assume that PMX464 similarly prevented translocation
of p65. Our observation that PMX464 prevented rapid
degradation of IkB and also prevented phosphorylation of
IkBa, normally a prerequisite for degradation, would support
this assumption. It also seemed likely that PMX464 would in
some way inhibit, either directly or indirectly, IKK activity as
this enzyme is solely responsible for phosphorylating IkB.
A previous study with a gold compound, auranofin, which
like PMX464 inhibits thiol groups, directly prevented IKK
activity by modifying the Cys-179 of the IKK-b subunit (Jeon
et al., 2003). It seems less likely that PMX464 has a similar
direct effect on IKK, because our results suggested that
PMX464 did not prevent IKK activity when added directly to
the immunoprecipitated IKK. Our findings are also similar to
those of a previous study showing that curcumin blocks
intestinal epithelial cell gene expression by inhibiting the
upstream signals leading to IKK activation (Jobin et al.,
1999). As PMX464 prevented TNF-a-and IL-1b-induced IKK
activity and, in general, IL-1b and TNF pathways vary
considerably upstream of IKK, this would suggest that
PMX464 acts in close proximity to IKK. Thus, it seemed
plausible that PMX464 would block IKK activity, indirectly,
possibly as a consequence of inhibiting Trx activity.
We confirmed that PMX464 inhibited Trx activity with an
IC50 of 20mM, which was similar to the previously published
results of 23mM (Pallis et al., 2003). We also showed that the
insulin reducing activity of A549 cell lysates was reduced by
pretreatment of the cells with PMX464. However, by contrast
to the effect of PMX464, genetic silencing of Trx had no
effect on the expression of ICAM-1 or, indeed, markers of
activation in the NF-kB pathway. How could this difference
be explained? We know that PMX464 is not an indiscrimi-
nate thiol inhibitor (Dr T Bradshaw, personal communica-
tion). However, other putative cellular protein targets have
been identified as potential molecular targets for quinols
including b-tubulin, heat-shock protein 60 and peroxiredoxin
1 (Chew et al., 2006). The extent to which inhibition of
these proteins might impact on the proinflammatory
response in lung epithelial cells is unclear. A recent paper
showed that a number of antitumour quinols related to
PMX464, inhibit thioredoxin reductase activity rather
than Trx activity (Chew et al., 2008), a process that
occurs, rapidly, in both cell-based assays and cell-free systems
(Dr T Bradshaw, personal communication). Although a
previous study showed no inhibition of TrxR with PMX464
in a cell-free system (Mukherjee et al., 2005, 2007) it is likely
that the studies were not carried out sufficiently early to
detect the inhibition of TrxR.
Certainly, we have unpublished data that would suggest
that PMX464 can reduce, by approximately 25%, TrxR
activity in cell lysates from A549 cells. Thus, one explanation
for the discrepancy between inhibition seen with PMX464
and Trx siRNA is that in order to achieve an anti-
inflammatory effect directed at the Trx system in lung
epithelial cells, Trx and TrxR should both be targeted. In
particular, this might be necessary with A549 cells as
expression of TrxR is high in lung cancer cell lines (Soini
et al., 2001). It is possible that an excess of TrxR could render
the remaining Trx (30%) in Trx siRNA-treated A549 cells
sufficiently active to cause ICAM-1 expression and increase
levels and phosphorylation of IkB-a.
Thus, it is of note that other studies investigating the
intracellular role of the Trx system have used siRNA against
either Trx or TrxR to demonstrate the inhibition. For
example, siRNA against TrxR prevented TrxR and haem
oxygenase (HO)-1 expression in endothelial cells, an effect
that confirmed results with a pharmacological inhibitor,
DNCB (Trigona et al., 2006). In this study, siRNA directed
against a region located 30bp downstream of the ATG start
codon of TrxR1, significantly decreased TrxR1 mRNA (87%),
protein (63%) and activity levels (41%) strongly suggesting
that complete elimination of protein expression is unusual
in studies using siRNA. Another study used two different
duplices to inhibit Trx-1 and revealed a role of Trx in
apoptosis in malignant mesothelioma cells (Freeman and
Neuzil, 2006). A further study showed that the down-
regulation of Trx in MCF-7 cells decreased expression of
p53 protein, caspase 7 and, in response to daunomycin,
expression of cleaved PARP (Ravi et al., 2005). Finally, a study
by Gorreta et al. (2005) used siRNA against TrxR and carried
out RNA and cDNA microarrays; they concluded that the
TrxR/Trx system affects a number of cellular processes by
regulating the activity of transcription factors, leading to
changes in gene expression. Thus, in future studies, we
propose to employ siRNA against TrxR alone and in
combination with siRNA against Trx to investigate the role
of the Trx system in proinflammatory activation of A549
epithelial cells. Moreover, we also propose to compare
the effects of Trx and/or TrxR siRNA in A549 cells to their
effects in primary epithelial cells, as primary cells express
lower TrxR levels (Soini et al., 2001) and thus, it might be
possible to detect an inhibition that could be masked in
A549 cells.
In summary, our data show that PMX464 downregulates
IL-1b-induced proinflammatory activation of A549 lung
epithelial cells through suppression of IKK activity and
NF-kB activation. The effects with PMX464 were not
mirrored by silencing Trx expression suggesting that
PMX464 has therapeutic anti-inflammatory properties,
which might result from the inhibition of other proteins
with the Trx motif in addition to Trx. One possibility is TrxR,
and this will be an important focus for future research.
Acknowledgements
MEC was supported by a Wellcome Trust Clinical Training
Fellowship, AB-G by a Wellcome Trust University Award, LP
PMX464 inhibits NF-jB in alveolar epithelial cells
ME Callister et al 670
British Journal of Pharmacology (2008) 155 661–672by the British Lung Foundation and SKL by the British Heart
Foundation. We thank Dr Tracey Bradshaw for her helpful
comments on the manuscript.
Conflict of interest
ADW is a consultant to Pharminox, a company who hold a
license for therapeutic applications of PMX464.
References
Alexander SPH, Mathie A, Peters JA (2008). Guide to receptors
and channels (GRAC), 3rd ed. Brit J Pharmacol 153 (Suppl 2):
S1–S209.
Bergmann M, Hart L, Lindsay M, Barnes PJ, Newton R (1998).
IkappaBalpha degradation and nuclear factor-kappaB DNA bind-
ing are insufficient for interleukin-1beta and tumor necrosis
factor-alpha-induced kappaB-dependent transcription. Require-
ment for an additional activation pathway. J Biol Chem 273:
6607–6610.
Birrell MA, Hardaker E, Wong S, McCluskie K, Catley M, De Alba J
et al. (2005). Ikappa-B kinase-2 inhibitor blocks inflammation in
human airway smooth muscle and a rat model of asthma. Am J
Respir Crit Care Med 172: 962–971.
Blease K, Chen Y, Hellewell PG, Burke-Gaffney A (1999). Lipoteichoic
acid inhibits lipopolysaccharide-induced adhesion molecule
expression and IL-8 release in human lung microvascular
endothelial cells. J Immunol 163: 6139–6147.
Burke-Gaffney A, Callister ME, Nakamura H (2005). Thioredoxin:
friend or foe in human disease? Trends Pharmacol Sci 26:
398–404.
Burke-Gaffney A, Hellewell PG (1996). Tumour necrosis factor-alpha-
induced ICAM-1 expression in human vascular endothelial and
lung epithelial cells: modulation by tyrosine kinase inhibitors.
Br J Pharmacol 119: 1149–1158.
Callister ME, Burke-Gaffney A, Quinlan GJ, Nicholson AG,
Florio R, Nakamura H et al. (2006). Extracellular thioredoxin
levels are increased in patients with acute lung injury. Thorax 61:
521–527.
Castro AC, Dang LC, Soucy F, Grenier L, Mazdiyasni H, Hottelet M
et al. (2003). Novel IKK inhibitors: beta-carbolines. Bioorg Med
Chem Lett 13: 2419–2422.
Catley MC, Cambridge LM, Nasuhara Y, Ito K, Chivers JE, Beaton A
et al. (2004). Inhibitors of protein kinase C (PKC) prevent activated
transcription: role of events downstream of NF-kappaB DNA
binding. J Biol Chem 279: 18457–18466.
Catley MC, Chivers JE, Holden NS, Barnes PJ, Newton R (2005).
Validation of IKK beta as therapeutic target in airway inflamma-
tory disease by adenoviral-mediated delivery of dominant-nega-
tive IKK beta to pulmonary epithelial cells. Br J Pharmacol 145:
114–122.
Chew EH, Lu J, Bradshaw TD, Holmgren A (2008). Thioredoxin
reductase inhibition by antitumor quinols: a quinol pharmaco-
phore effect correlating to antiproliferative activity. FASEB J 22:
2072–2083.
Chew EH, Matthews CS, Zhang J, McCarroll AJ, Hagen T, Stevens MF
et al. (2006). Antitumor quinols: role of glutathione in modulating
quinol-induced apoptosis and identification of putative cellular
protein targets. Biochem Biophys Res Commun 346: 242–251.
Chomczynski P, Sacchi N (1987). Single-step method of RNA
isolation by acid guanidinium thiocyanate-phenol-chloroform
extraction. Anal Biochem 162: 156–159.
Dandreaa T, Bajaka E, Wa ¨rnga ˚rda L, Cotgreave IA (2002). Protein S-
glutathionylation correlates to selective stress gene expression and
cytoprotection. Arch Biochem Biophys 406: 241–252.
Freeman RE, Neuzil J (2006). Role of thioredoxin-1 in apoptosis
induction by alpha-tocopheryl succinate and TNF-related
apoptosis-inducing ligand in mesothelioma cells. FEBS Lett 580:
2671–2676.
Frelin C, Imbert V, Griessinger E, Loubat A, Dreano M, Peyron JF
(2003). AS602868, a pharmacological inhibitor of IKK2, reveals the
apoptotic potential of TNF-alpha in Jurkat leukemic cells.
Oncogene 22: 8187–8194.
Ghosh S, Karin M (2002). Missing pieces in the NF-kappaB puzzle.
Cell 109 (Suppl): S81–S96.
Gorreta F, Runfola TP, VanMeter AJ, Barzaghi D, Chandhoke V,
Del Giacco L (2005). Identification of thioredoxin reductase
1-regulated genes using small interference RNA and cDNA
microarray. Cancer Biol Ther 4: 1079–1088.
Gupta S, Afaq F, Mukhtar H (2002). Involvement of nuclear factor-
kappa B, Bax and Bcl-2 in induction of cell cycle arrest and
apoptosis by apigenin in human prostate carcinoma cells.
Oncogene 21: 3727–3738.
Henderson Jr WR, Chi EY, Teo JL, Nguyen C, Kahn M (2002). A small
molecule inhibitor of redox-regulated NF-kappa B and activator
protein-1 transcription blocks allergic airway inflammation in a
mouse asthma model. J Immunol 169: 5294–5299.
Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N,
Hayashi T et al. (2002). NF-kappa B as a therapeutic target in
multiple myeloma. J Biol Chem 277: 16639–16647.
Holmgren A, Bjornstedt M (1995). Thioredoxin and thioredoxin
reductase. Methods Enzymol 252: 199–208.
Jeon KI, Byun MS, Jue DM (2003). Gold compound auranofin
inhibits IkappaB kinase (IKK) by modifying Cys-179 of IKKbeta
subunit. Exp Mol Med 35: 61–66.
Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, Brenner DA et al.
(1999). Curcumin blocks cytokine-mediated NF-kappa B
activation and proinflammatory gene expression by inhibiting
inhibitory factor I-kappa B kinase activity. J Immunol 163:
3474–3483.
Koura T, Gon Y, Hashimoto S, Azuma A, Kudoh S, Fukuda Y et al.
(2000). Expression of thioredoxin in granulomas of sarcoidosis:
possible role in the development of T lymphocyte activation.
Thorax 55: 755–761.
Lentsch AB, Ward PA (2000). The NFkappaBb/IkappaB system
in acute inflammation. Arch Immunol Ther Exp (Warsz) 48:
59–63.
Lillig CH, Holmgrem A (2007). Thioredoxin and related
molecules–from biology to health and disease. Antioxid Redox
Signal 9: 25–47.
Misra-Press A, McMillan M, Cudaback E, Qabar M, Ruan F, Nguyen M
et al. (2002). Identification of a Novel Inhibitor of the NF-kB
Pathway. Curr Med Chem-Anti-Inflammatory and Anti-Allergy Agents 1:
29–39.
Mukherjee A, Huber K, Evans H, Lakhani N, Martin S (2007). A
cellular and molecular investigation of the action of PMX464, a
putative thioredoxin inhibitor, in normal and colorectal cancer
cell lines. Br J Pharmacol 151: 1167–1175.
Mukherjee A, Westwell AD, Bradshaw TD, Stevens MF, Carmichael J,
Martin SG (2005). Cytotoxic and antiangiogenic activity of
AW464 (NSC 706704), a novel thioredoxin inhibitor: an in vitro
study. Br J Cancer 92: 350–358.
Newton R, Holden NS, Catley MC, Oyelusi W, Leigh R, Proud D et al.
(2007). Repression of inflammatory gene expression in human
pulmonary epithelial cells by small-molecule IkappaB kinase
inhibitors. J Pharmacol Exp Ther 321: 734–742.
Pallis M, Bradshaw TD, Westwell AD, Grundy M, Stevens MF,
Russell N (2003). Induction of apoptosis without redox
catastrophe by thioredoxin-inhibitory compounds. Biochem
Pharmacol 66: 1695–1705.
Rahman I, Yang SR, Biswas SK (2006). Current concepts of redox
signaling in the lungs. Antioxid Redox Signal 8: 681–689.
Ravi D, Muniyappa H, Das KC (2005). Endogenous thioredoxin is
required for redox cycling of anthracyclines and p53-dependent
apoptosis in cancer cells. J Biol Chem 280: 40084–40096.
Soini Y, Kahlos K, Na ¨pa ¨nkangas U, Kaarteenaho-Wiik R, Sa ¨ily M,
Koistinen P et al. (2001). Widespread Expression of Thioredoxin
and Thioredoxin Reductase in Non-Small Cell Lung Carcinoma.
Clin Cancer Res 7: 1750–1757,.
Souza DG, Vieira AT, Pinho V, Sousa LP, Andrade AA, Bonjardim CA
et al. (2005). NF-kappaB plays a major role during the systemic and
local acute inflammatory response following intestinal reperfu-
sion injury. Br J Pharmacol 145: 246–254.
PMX464 inhibits NF-jB in alveolar epithelial cells
ME Callister et al 671
British Journal of Pharmacology (2008) 155 661–672Tiitto L, Kaarteenaho-Wiik R, Sormunen R, Holmgren A, Paakko P,
Soini Y et al. (2003). Expression of the thioredoxin system in
interstitial lung disease. J Pathol 201: 363–370.
Trigona WL, Mullarky IK, Cao Y, Sordillo LM (2006). Thioredoxin
reductase regulates the induction of haem oxygenase-1
expression in aortic endothelial cells. Biochem J 394:
207–216.
Wells G, Berry JM, Bradshaw TD, Burger AM, Seaton A, Wang B et al. (2003).
4-Substituted 4-hydroxycyclohexa-2,5-dien-1-ones with selective activ-
ities against colon and renal cancer cell lines. JM e dC h e m46:5 3 2 – 5 4 1 .
This article is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0
Licence. To view a copy of this licence, visit http://creativecommons.org/licences/by-nc-nd/3.0/
BJPOpen    This article is available free of charge on the BJP website (http://www.brjpharmacol.org).
PMX464 inhibits NF-jB in alveolar epithelial cells
ME Callister et al 672
British Journal of Pharmacology (2008) 155 661–672